Our Story

Scipher Medicine holds a fundamental conviction that patients with autoimmune diseases deserve a simple answer to their treatment plans using scientifically-backed data.

We are driven by data, passionate about improving healthcare, determined to push science, and convinced the only way to do it is through collaboration. 

From our founders questioning diseases after the Human Genome Project to our dedication to helping the hundreds of millions of patients who are prescribed drugs that don’t work, we believe the average isn’t good enough.  

2001

Human Genome Project successfully finishes.

2003

Our founders Drs. Joseph Loscalzo and Laszlo Barabasi began building the map of human disease biology that explains how proteins expressed from the human genome interact to cause specific diseases.

2013

The map grew to cover 89% of all physically proven protein - protein interactions in human cells, revealing the underlying biological processed causing many of the most common and difficult to treat diseases.

2015

Scipher Medicine is founded.

2016

Research begins to develop predictive drug response tests.

2017

Scipher applies its research to develop a test for predicting drug response to anti-TNF therapies after discussions with commercial payers identified these drugs as its largest pain point for reimbursement, a $45 billion market.

2018

Scipher completes its Series A funding and observational study for its anti-TNF response test in rheumatoid arthritis. Research begins in treatment development in inflammatory bowel disease (IBD).

2019

Scipher kicks of its prospective trials for PrismRA and PrismUC and identifies multiple novel targets in IBD.

Our team comes from a wide range of backgrounds and nationalities to question the status quo together and move the healthcare industry forward. 

Our Team